title: [Features of dynamics of sera cytokines in patients with erythema multiforme during immunotherapy].
abstract: OBJECTIVE
  Study the features of cytokine profile in patients with exudative erythema multiforme (EME) and dynamics of basal level of pro-inflammatory and anti-inflammatory cytokines during immunotherapy.
  
  
  METHODS
  39 adult patients with erythema multiforme were examined. The patients were split into groups based on therapy variant. One group (14 individuals) received Immunovac-VP-4 against the background of basic therapy; the other (12 individuals)--cagocel against the background of basic therapy; comparison group (13 individuals) received only basic therapy; 15 individuals composed a group of healthy individuals. All the patients had the level of pro-, anti-inflammatory and regulatory cytokines determined in blood sera by solid-phase EIA method by using Biosource (Austria) test-systems at the beginning of the study and after the therapy.
  
  
  RESULTS
  In patients with exudative erythema multiforme Immunovac-VP-4 therapy facilitated a significant (p < 0.05) increase of serum IFN-gamma level, insignificant (p > 0.05) increase of IL-1beta and decrease of IL-17. Whereas cagocel lead to an increase of IL-4 (p > 0.05), IL-2, IFN-gamma (p < 0.05) and decrease of TGF-beta and IL-12 (p < 0.05). At the same time basic therapy facilitated a significant increase of IL-5 and decrease of IL-6, IL-12, IFN-gamma.
  
  
  CONCLUSIONS
  Immunovac-VP-4 facilitates the increase of secretion of IFN-gamma, IL-1beta against the background of TGF-beta that facilitates normalization of cooperation of cells in immune response including against viral infections, and thereby influencing the trigger factor in EME patients.
authors.forename: E V
authors.initials: EV
authors.lastname: Sorokina
authors.forename: N K
authors.initials: NK
authors.lastname: Akhmatova
authors.forename: V G
authors.initials: VG
authors.lastname: Khomenkov
mesh_terms: D000293:Adolescent; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D016207:Cytokines / Q000097:blood* / Q000276:immunology; D004892:Erythema Multiforme / Q000097:blood* / Q000276:immunology / Q000628:therapy*; D005260:Female; D006072:Gossypol / Q000008:administration & dosage / Q000031:analogs & derivatives; D006801:Humans; D007167:Immunotherapy; D008297:Male; D008875:Middle Aged
chemical_list: D000893:Anti-Inflammatory Agents; D016207:Cytokines; C056991:cagocel-1; D006072:Gossypol